CareDx, Inc. (CDNA) — 分析摘要
CareDx, Inc.（CDNA）的市值为1.49十亿美元，最近一年的营收同比增长了+13.8%。净利润率为-5.6%。当前市盈率为-181.4倍。
核心要点
- 营收同比变化+13.8%
- 净利润率-5.6%
- 市盈率-181.4倍
与SERVICES-MEDICAL LABORATORIES板块的其他公司相比，CDNA的营收增长为+13.8%，市盈率为-181.4倍。
CareDx, Inc. (CDNA)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
行业
SERVICES-MEDICAL LABORATORIES
员工人数
765
总部
BRISBANE, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。